blood poisoning/sepsis
Conditions
Interventions
The day of the experiment, prehydration will be performed by infusion of 1.5 L
2.5% glucose/0.45% saline solution in 1 hour before LPS administration. LPS
derived from E coli O:113 will be injected
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: One male volunteer who masters the concentration/meditation technique.
Exclusion criteria
Exclusion criteria: Use of any medication. Smoking. Bleeding disorder. Previous spontaneous vagal collapse. History, signs or symptoms of cardiovascular disease. Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block. Hypertension (defined as RR systolic > 160 or RR diastolic > 90). Hypotension (defined as RR systolic 120 µmol/l). Liver enzyme abnormalities or positive hepatitis serology. Positive HIV serology or any other obvious disease associated with immune deficiency. Febrile illness in the week before the LPS challenge. Participation in another drug trial or donation of blood 3 months prior to the planned LPS challenge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the concentration of circulating TNF-a following LPS administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters include temperature, hemodynamic parameters (blood pressure and heart rate), illness score, catecholamines, heart rate variability, muscle sympathetic nerve activity, electroencephalography, other circulating cytokines (IL6, IL10 and IL1RA) and subclinical renal injury. | — |
Countries
Netherlands
Outcome results
None listed